Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (NASDAQ:BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.

This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential of macrocyclic peptides as a novel therapeutic modality for rare diseases and oncology. Macrocyclic peptides are a unique class of therapeutic compounds characterized by large, cyclic structures that offer significant advantages over traditional therapies such as small molecules and monoclonal antibodies. Their unique structure provides high stability, potent binding affinity, and the ability to access difficult-to-reach intracellular targets, positioning them as a promising therapeutic class.